Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kovnar, E. H.
Right arrow Articles by Fairclough, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kovnar, E. H.
Right arrow Articles by Fairclough, D. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 8, 330-336, Copyright © 1990 by American Society of Clinical Oncology


ARTICLES

Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study

EH Kovnar, SJ Kellie, ME Horowitz, RA Sanford, JW Langston, RK Mulhern, JJ Jenkins, EC Douglass, EE Etcubanas and DL Fairclough
Department of Neurology, St Jude Children's Research Hospital, Memphis, TN 38101.

Medulloblastoma, pineoblastoma, and cerebral neuroblastoma are malignant embryonal tumors of the CNS that may demonstrate similar histologic features, a propensity for neuraxis dissemination and sensitivity to radiation therapy and, in certain cases, chemotherapy. To evaluate the activity of preirradiation chemotherapy in such tumors, 11 newly diagnosed children with measurable residual disease and characteristics indicative of poor prognosis were treated postoperatively with cisplatin (CDDP) and etoposide (VP-16). Responses graded on the basis of radiographic findings in areas of either macroscopic residual tumor or metastatic disease included two complete responses (CRs), eight partial responses (PRs), and one stable disease (SD). Acute and subacute toxicity consisted of high-frequency hearing loss in four patients, reversible signs and symptoms of increased intracranial pressure in two patients, and transient neutropenia. Seven of eight patients with high-risk medulloblastoma and two of two with pineoblastoma remain free of tumor progression following neuraxis irradiation at 8 to 48 months postdiagnosis (median, 18 months). CDDP and VP-16 is a highly active drug combination when given before irradiation in children with high-risk medulloblastoma and other malignant embryonal tumors of the CNS, producing objective responses in at least one site of measurable disease in 10 of 11 newly diagnosed patients, including all of five with gross neuraxis dissemination.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JCOHome page
L. Gandola, M. Massimino, G. Cefalo, C. Solero, F. Spreafico, E. Pecori, D. Riva, P. Collini, E. Pignoli, F. Giangaspero, et al.
Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma
J. Clin. Oncol., February 1, 2009; 27(4): 566 - 571.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. F. Stewart, L. C. Iacono, M. Chintagumpala, S. J. Kellie, D. Ashley, W.C. Zamboni, M.N. Kirstein, M. Fouladi, L. G. Seele, D. Wallace, et al.
Results of a Phase II Upfront Window of Pharmacokinetically Guided Topotecan in High-Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor
J. Clin. Oncol., August 15, 2004; 22(16): 3357 - 3365.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. E. Taylor, C. C. Bailey, K. Robinson, C. L. Weston, D. Ellison, J. Ironside, H. Lucraft, R. Gilbertson, D. M. Tait, D. A. Walker, et al.
Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study
J. Clin. Oncol., April 15, 2003; 21(8): 1581 - 1591.
[Abstract] [Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
R. J. Packer, P. Cogen, G. Vezina, and L. B. Rorke
Medulloblastoma: Clinical and biologic aspects
Neuro-oncol, July 1, 1999; 1(3): 232 - 250.
[Abstract] [PDF]


Home page
JCOHome page
R. J. Packer, J. Goldwein, H. S. Nicholson, L. G. Vezina, J. C. Allen, M. D. Ris, K. Muraszko, L. B. Rorke, W. M. Wara, B. H. Cohen, et al.
Treatment of Children With Medulloblastomas With Reduced-Dose Craniospinal Radiation Therapy and Adjuvant Chemotherapy: A Children's Cancer Group Study
J. Clin. Oncol., July 1, 1999; 17(7): 2127 - 2127.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. J. Packer and J. L. Finlay
Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Oncologist, December 1, 1996; 1(6): 381 - 393.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
I. F. Pollack
Brain Tumors in Children
N. Engl. J. Med., December 1, 1994; 331(22): 1500 - 1507.
[Full Text]


Home page
J Child NeurolHome page
F. H. Tomlinson, B. W. Scheithauer, F. B. Meyer, W. A. Smithson, E. G. Shaw, G. M. Miller, and R. V. Groover
Topical Review Article: Medulloblastoma: I. Clinical, Diagnostic, and Therapeutic Overview
J Child Neurol, April 1, 1992; 7(2): 142 - 155.
[Abstract] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 1990 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online